Carl Zeiss Meditec offers a high-quality medtech franchise with a bruised margin profile, where successful ProfitUp execution and China normalization could turn today’s valuation reset into a powerful multi-year rerating.
Overview
Carl Zeiss Meditec AG is a premium medical technology franchise focused on Ophthalmology and Microsurgery, with Ophthalmology contributing 76.1% of revenue and Microsurgery 23.9%. Its model blends capital equipment, recurring consumables, and services, allowing installed systems such as VISUMAX lasers and surgical microscopes to drive ongoing treatment-pack, implant, and maintenance revenue. The company’s strategic edge lies in **integrated clinical workflows**, linking diagnostics, software, and surgery through proprietary platforms rather than selling standalone devices. That supports switching costs, premium pricing, and strong customer retention.
Near-term performance has been weak. In H1 FY 2025/26, revenue fell 5.7% to €991.0 million and adjusted EBITA dropped 46.3% to €60.5 million, with margin compressing to 6.1% from 10.7%. Pressure came from a €46 million FX headwind, Chinese tender and pricing disruptions, and slower US capital spending. Management responded with the **ProfitUp** restructuring plan targeting more than €200 million of structural earnings improvement by FY 2028/29.
Valuation has reset sharply to 1.11x sales and 19.98x normalized P/E versus a 5-year average P/E of 36.4x. The key debate is whether this is cyclical margin compression or structural erosion. The report argues the business moat remains intact, while catalysts include **ProfitUp execution, China tender re-entry, and new CEO Bronwyn Brophy O'Connor’s turnaround leadership**.